Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
52 employees
Cue Biopharma, Inc.: A biotech firm innovating protein biologics for cancer and autoimmune diseases.
HQ
Founded
2014
Cue Biopharma, Inc. is a biotechnology company dedicated to discovering and developing medicines for cancers and autoimmune diseases. The company focuses on the design and clinical development of protein biologics, leveraging advancements in immunology and immuno-oncology to create targeted therapies. Cue Biopharma serves customers primarily in Massachusetts.
Cue Biopharma has achieved significant milestones in advancing its pipeline of biologic drugs, contributing to the field of targeted cancer and autoimmune disease treatments. The company's innovative approach has garnered attention within the biotech community, positioning it as a key player in the development of next-generation immunotherapies.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Biopharmaceuticals
Technology
Biotech
Tags
Healthtech
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Cue Biopharma founded?
Cue Biopharma was founded in 2014.
Where is Cue Biopharma's headquarters located?
Cue Biopharma's headquarters is located in Boston, MA, US.
When was Cue Biopharma's last funding round?
Cue Biopharma's most recent funding round was for $30M (USD) in November 2022.
How many employees does Cue Biopharma have?
Cue Biopharma has 52 employees as of Feb 6, 2024.
How much has Cue Biopharma raised to-date?
As of July 05, 2023, Cue Biopharma has raised a total of $56.4M (USD) since Nov 14, 2022.
Add Comparison
Total Raised to Date
$56.4M
USD
Last Update Nov 14, 2022
Last Deal Details
$30M
USD
Nov 14, 2022
Post Ipo Equity
Current Employees
52
Last updated: Feb 6, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts